Sichuan Glory Industrial Park Management Co., Ltd. is a holding company of Zhong Jian Lian Biomedicine Technology (Sichuan) Co., Ltd.(hereinafter referred to as the Company).Founded on January 2,2020 and located in the“China Shifang International Biomedical Technology Industrial Park” in the southern area of Shifang Economic Development Zone in Sichuan Province, the Company is a hi-tech enterprise with theinternational leading patent technologies for therapeutic and biomedical applications and pilot testing of bio-macromolecular drugs, as well as physical sterilization-based new disinfectant applications, and other proprietary intellectual property rights in medical devices. 

The Company introduces two technical routes with comprehensive international advanced microbial fermentation and mammalian cell culture, has the technical team with advantage of generation gap in many technical areas, establishes the “platform for pilot testing of bio-macromolecular drugs and large-scale cGMP base (CDMO)” in China Shifang International Biomedical Technology Industrial Park in conformity with the standards of China FDA, US FDA and EU EMA, creates the world-class biopharmaceutical research and development and production base, form a complete industrial chain covering from drug discovery to new process and production technology, provide the contract development and manufacturing organization (CDMO) services for the bio-macromolecular drugs in large batch and high quality, which are exclusive in China and advanced in the world, gradually derives many innovative biological research and development firms, attracts the hi-tech talents engaged in biological medicine to form the high-density gathering, so as to lead, attract and assemble the stationing of Chinese and international biological medicine companies and enterprises, and build Shifang into a new biomedical industry center in China and even in the world. 

The Company’s international team has rich experience in research and development of new drugs at home and abroad, and relies on the technical platform of the Institute of Biophysics of the Chinese Academy of Sciences.The Company is specialized in the research and development of new drugs for rare metabolic diseases with huge market potential, and realizes efficient research and development transformation of the projects through the optimized research and development modes; at present, the Company has developed 10 new drug research and development projects related to fat metabolism, and has established three public technology development service platforms including dual specific antibody drug, long-acting protein drug, and bio-macromolecular drug with independent intellectual property rights; the Company has the first-type new drug product pipelines with great clinical application potential, realizes the commercial transformation of research and development projects, drives the organic development of the regional biomedical industry chain and ecosystem, and becomes an innovative drug research and developmententerprise with global influence in the field of metabolic diseases.